nimotuzumab,ibrutinib
biocon,daiichi sankyo,oncoscience,janssen,abbvie
['lymsm', 'nimotuzumab', 'pancsm', 'pancreatic', 'lymphoma', 'mantle,(-dismantle)']
today s new #cancerresearch from #asco22: 1. adding nimotuzumab for #pancreaticcancer = os. 2. adding ibrutinib for mantle cell #lymphoma = pfs by 50% for older adults #pancsm #lymsm
Timely, trusted, compassionate doctor-approved info from @ASCO
https://t.co/K04SLVsoar

We cannot answer individual medical questions.

Retweet ?Endorsement